Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation

This study has been terminated.
(Pfizer Taiwan has received approval letter for criziontinb on March and expect obtaining license by May 2013.)
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01637597
First received: June 28, 2012
Last updated: January 7, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)